An Update on HD Clinical Trials in Canada

The session will cover current and upcoming clinical trials of relevance to patients and families affected by Huntington’s disease in
Canada. The focus of the talk will be on huntingtin-lowering therapies for HD and I will introduce the scientific basis for these approaches. The global Roche Tominersin program will be reviewed in significant detail in this talk, I will describe the current Wave ASO program, and will also discuss the upcoming PTC trial (which will be called PIVOT-HD). The PROOF-HD study, a non-huntingtin lowering study of pridopidine in HD that is being sponsored by Prilenia, will be the final clinical trial covered in this session.